Actively Recruiting
Non-invasive Monitoring of Miscarriage Using Cell-Free DNA Blood Test Study of Early Pregnancy Loss in Women Aged 18 to 45
Led by Chinese University of Hong Kong · Updated on 2024-11-12
150
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research focuses on miscarriage in the first trimester, particularly examining the usefulness of cell-free DNA cfDNA in early pregnancy. The study aims to determine cfDNA levels and compare these results with product of conception POC testing and standard karyotyping. It highlights that pregnancies achieved by assisted reproductive technologies ART are closely monitored, while spontaneous abortion rates in natural conceptions are harder to assess. Women undergoing ART may have a higher vulnerability to miscarriage, making this research important for understanding chromosomal causes. Participants will not receive any treatment or intervention as this is an observational study involving routine procedures. The study involves monitoring and testing cfDNA levels and comparing these with genetic analysis of pregnancy tissue. The primary and secondary outcome measures will be evaluated at 15 weeks of pregnancy. During the study, women attending early pregnancy loss clinics or those who have received ART, along with their partners, will have their cfDNA levels measured and compared to POC testing results. Researchers will collect data through blood tests and genetic analyses without providing interventions. The total participation timeline includes assessments up to 15 weeks of pregnancy to monitor cfDNA and aneuploidy results, ensuring close observation of early pregnancy loss.
CONDITIONS
Brief Title
Non-invasive Monitoring of Miscarriage
Research Team
P
PUI WAH JACQUELINE CHUNG
Y
Yee Lee Elaine NG
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here